Deutsche Bank Cuts PT on Sanofi (SNY) – Here’s Why

1 hour ago 1

Noor Ul Ain Rehman

Sat, June 27, 2026 astatine 2:10 PM CDT 1 min read

Sanofi (NASDAQ:SNY) is 1 of the champion debased volatility stocks to bargain nether $50. Deutsche Bank chopped the terms people connected Sanofi (NASDAQ:SNY) to EUR 95 from EUR 100 connected June 15 and maintained a Buy standing connected the shares. For reference, successful its fiscal results for fiscal Q1 2026, Sanofi (NASDAQ:SNY) reported double-digit income and concern EPS growth. Fiscal Q1 income maturation was 13.6% astatine CER, portion concern net per stock reached €1.88. Pharma launches income roseate by 49.6% and reached €1.2 billion, driven chiefly by Ayvakit, ALTUVIIIO, and Sarclisa.

Is Sanofi (SNY)the Best Gene-Editing Stock to Buy?

Management further reported that Dupixent income grew by 30.8% to €4.2 billion, suggesting a coagulated commencement to 2026. Similarly, vaccine income grew by 2.1% to €1.3 billion, benefiting from Heplisav-B. Sanofi (NASDAQ:SNY) besides announced that Research and Development expenses reached €1.7 billion, up by 1.5%, portion selling and wide expenses reached €2.3 billion, up by 11.6%, chiefly owed to the effect of caller acquisitions.

Sanofi (NASDAQ:SNY) researches, produces, and distributes pharmaceutical products. The company's operations are divided into the Pharmaceuticals, Consumer Healthcare, and Vaccines segments.

While we admit the imaginable of SNY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Stocks That Will Make You Rich successful 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey connected Google News.

Read Entire Article